Hennion & Walsh Asset Management Inc. Has $409,000 Position in Sanofi (NASDAQ:SNY)

Hennion & Walsh Asset Management Inc. cut its position in shares of Sanofi (NASDAQ:SNY) by 32.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,095 shares of the company’s stock after selling 3,407 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Sanofi were worth $409,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stablepoint Partners LLC increased its position in shares of Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after purchasing an additional 189 shares during the period. TCTC Holdings LLC increased its holdings in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares during the period. HB Wealth Management LLC raised its stake in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after buying an additional 221 shares in the last quarter. Insigneo Advisory Services LLC lifted its holdings in shares of Sanofi by 3.3% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after acquiring an additional 228 shares during the period. Finally, Pinnacle Bancorp Inc. boosted its position in shares of Sanofi by 24.6% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company’s stock valued at $71,000 after acquiring an additional 242 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on SNY shares. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 14th. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $54.36 on Tuesday. Sanofi has a 1-year low of $44.05 and a 1-year high of $58.97. The company has a 50 day moving average of $56.08 and a 200-day moving average of $51.84. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $137.96 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS. On average, equities analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.